CRISPR-Cas9 Gene Editing Protects from the A53T-SNCA Overexpression-Induced Pathology of Parkinson's Disease In Vivo.
Yoon HH, Ye S, Lim S, Jo A, Lee H, Hong F, Lee SE, Oh SJ, Kim NR, Kim K, Kim BJ, Kim H, Lee CJ, Nam MH, Hur JW, Jeon SR.
Yoon HH, et al. Among authors: kim h, kim nr, kim bj, kim k.
CRISPR J. 2022 Feb;5(1):95-108. doi: 10.1089/crispr.2021.0025.
CRISPR J. 2022.
PMID: 35191750